Dissolution Apparatus 1 vs 2 (Basket vs Paddle): A Selection Guide for Pharma QC Labs

Dissolution Apparatus 1 vs 2 (Basket vs Paddle): A Selection Guide for Pharma QC Labs

Technical content reflects Huanghai Pharmaceutical Instruments' engineering specifications and 40+ years of pharmaceutical QC equipment manufacturing experience. Huanghai Pharmaceutical Instruments' core R&D team, led by Academician Hou Huimin of the Chinese Academy of Engineering, has secured nearly 100 patents, and the company serves clients in 30+ countries.

The choice between USP Apparatus 1 (rotating basket) and Apparatus 2 (paddle) looks deceptively simple on paper. In practice, it is the single decision that locks in a dissolution method's behavior across batches, sites, formulation revisions, and regulatory submissions. Picking the wrong apparatus does not show up as a failed validation — it shows up later as coning artifacts, irreproducible sinker positioning, or an avoidable revalidation cycle when a generic developer needs to demonstrate F2 similarity against a paddle-based reference listed drug.

USP <711> Dissolution is harmonized with EP 2.9.3 and JP 6.10, and aligned in methodology with ChP 0931 — the four pharmacopoeias share Apparatus 1 and Apparatus 2 as the foundational basket and paddle configurations. The harmonization means the apparatus selection question is the same in every regulated market the lab serves; what differs is the dosage form, the coning behavior, and the throughput your release-testing schedule actually demands.

This guide walks through how a senior QC manager should make the apparatus decision, what the harmonized pharmacopoeias actually require, and how to size dissolution hardware (from a single-vessel research unit up through 12-channel automated sampling) against the testing volume your QC release schedule will produce.

At-a-Glance Comparison

The following table is the procurement-level summary. The technical reasoning behind each row is unpacked in the sections that follow.

Criterion Apparatus 1 — Rotating Basket (USP <711>) Apparatus 2 — Paddle (USP <711>)
Stirring element 40-mesh stainless steel cylindrical basket attached to a rotating shaft Two-bladed stainless steel paddle on a rotating shaft
Typical rotation speed 50–100 RPM (commonly 100 RPM for IR capsules) 50–75 RPM (commonly 50 RPM for IR tablets, 75 RPM for ER)
Dosage forms most suited Capsules (hard-shell and soft-gel), floating dosage forms, dosage forms that disintegrate into a buoyant mass, suppositories with non-disintegrating shells Conventional immediate-release tablets, modified-release tablets, coated tablets, orally disintegrating tablets, suspensions
Coning behavior Generally not subject to coning (basket physically contains the disintegrated mass) Coning at the vessel bottom is a well-documented artifact when paddle hydrodynamics under-mix the dome region directly beneath the paddle
Sinker requirement Not applicable (basket itself contains the dose) Mandatory for floating, sticking, or buoyant dosage forms; sinker geometry is part of the validated method
Regulatory precedent First-line apparatus for capsules and most soft-gel formulations in FDA OGD recommendations and the FDA Dissolution Methods Database First-line apparatus for the majority of IR and ER solid oral tablets in FDA OGD recommendations
Method transfer reproducibility Robust; basket position is mechanically fixed Sensitive to paddle height (25 ± 2 mm above the inner bottom), centering, and sinker placement
Best for: Encapsulated APIs, floating beads, gelatin shells, products at risk of coning in paddle configuration Conventional tablets and the majority of OGD-listed reference methods; default for most generic ANDA dissolution development

When to Pick Apparatus 1 (Basket)

The basket is the correct apparatus in five scenarios — most of which trace back to the physical geometry of the dosage form rather than to API chemistry.

1. Hard-shell and soft-gel capsules. Both gelatin and HPMC capsules tend to float when dropped into a 900 mL vessel of dissolution medium. A paddle vessel that lets a capsule drift around the vessel surface during the first 5–10 minutes is producing variable hydrodynamics over the dissolution profile's most sensitive sampling window. The basket physically contains the capsule from t = 0, so the sampling time points reflect the formulation's intrinsic release behavior rather than where the capsule happened to drift on a given run. FDA's Dissolution Methods Database lists Apparatus 1 as the recommended apparatus for the majority of capsule reference products in the OGD recommendations.

2. Floating dosage forms — gastro-retentive and effervescent. Gastro-retentive tablets and effervescent dosage forms are designed to float; in a paddle vessel they will sit on the surface and dissolve without ever contacting the high-shear region near the paddle blade. The basket apparatus avoids this confound by holding the dose in a controlled mesh enclosure regardless of buoyancy.

3. Dosage forms that disintegrate into a non-cohesive buoyant mass. Some immediate-release tablets disintegrate within the first 60 seconds into a fine particulate cloud that disperses unevenly in a paddle vessel. The basket retains the disintegrated mass within the mesh, allowing dissolution kinetics to be measured against a known retained-mass envelope rather than a stochastic dispersion pattern.

4. Suppositories and lipid-matrix dosage forms with insoluble shells. Suppositories that release API while the lipid base melts but retains a shell or residue are well-served by Apparatus 1 because the basket retains the residual mass for visual confirmation at the end of the run.

5. When the FDA OGD recommendation calls for it. For ANDA submissions, the simplest and most defensible apparatus choice is the one cited in the FDA Dissolution Methods Database for the reference listed drug (RLD). If the RLD method specifies Apparatus 1 at 100 RPM in 900 mL of 0.1 N HCl, the path of least regulatory friction is to match that method exactly. Any deviation requires a justification package and bioequivalence implications must be considered.

A 6-vessel basket-configured platform such as the RCZ-6N Intelligent Dissolution Tester is the standard entry-level workstation for capsule-heavy QC programs that need a USP <711> compliant unit for routine release testing. It supports basic audit trails per USP/ChP standards and ships with a built-in dual-replenishment cup configuration for sink-condition maintenance over extended profile runs.

When to Pick Apparatus 2 (Paddle)

The paddle is the default apparatus for the largest share of solid oral dosage forms produced today, but "default" is not the same as "always." The paddle wins in the following cases, with the well-known caveat that coning must be actively managed.

1. Conventional immediate-release tablets. A standard IR tablet that disintegrates uniformly in the first 5 minutes and produces a non-buoyant disintegrated mass is the textbook paddle case. The paddle generates radial flow that distributes the disintegrated solids around the vessel bottom, allowing the dissolved API to equilibrate with bulk medium at the sampling depth.

2. Modified-release matrix tablets. ER hydrophilic-matrix tablets, lipid-matrix tablets, and coated osmotic systems are designed to remain intact while releasing API over hours. The paddle apparatus holds the intact tablet at the vessel bottom (with a sinker if necessary) while sampling the bulk-phase concentration over the 12 to 24-hour release window.

3. Coated tablets and ODTs that produce a non-buoyant disintegrated mass. Film-coated tablets and orodispersible tablets with conventional excipient systems behave well in paddle vessels provided sinker geometry is validated and the formulation does not cone.

4. When the OGD recommendation calls for it. As with Apparatus 1, the path of least regulatory friction is to match the RLD method. The majority of OGD-listed methods for solid oral tablets specify Apparatus 2.

5. When a 12-vessel throughput envelope justifies the platform. QC labs running high-volume IR/ER tablet release testing benefit from a 12-vessel paddle configuration that processes a full dosage-strength sweep (e.g., 25 mg, 50 mg, 100 mg, 200 mg in triplicate) in a single run. The RCZ-12A Intelligent Dissolution Tester provides separate stirring control and an auto tablet-dropping function in a 12-vessel configuration designed for high-throughput release labs.

The Coning Problem — and How Senior QC Managers Actually Manage It

Coning is the formation of a conical mound of disintegrated solids directly beneath the paddle, in the dome region where paddle-induced flow is weakest. It produces dissolution profiles that systematically under-report release rate and that are sensitive to small changes in paddle height, vessel centering, and excipient grade. Coning is a paddle-specific artifact; it is not a basket-apparatus risk.

The standard QC playbook for managing coning, in order of preference:

  1. Confirm the apparatus selection is correct. If the formulation produces a heavily coning disintegration pattern, the question is whether Apparatus 1 (basket) was the right starting point. Switching apparatus mid-development is expensive but cheaper than fighting an irreproducible profile through validation.
  2. Increase paddle RPM within USP-validated ranges. Moving from 50 RPM to 75 RPM is a documented response in many cone-prone IR tablet methods. Going higher requires biorelevance and similarity-factor consideration.
  3. Consider a peak-vessel modification for products with persistent coning where apparatus and RPM changes are not viable. Peak vessels are a recognized but non-default approach and require a specific justification package.
  4. Validate sinker selection for buoyant fragments. A sinker is part of the validated method when the dosage form floats — and the validation includes sinker geometry, mass, and material. A change to a "comparable" sinker is a method change.

Coning is the single most common reason a paddle method that worked in development fails reproducibility at a second site. The discipline of method development is to characterize coning behavior on the original platform, lock the parameters, and treat any apparatus or sinker substitution as a method amendment requiring revalidation.

Method Development: Medium Selection Often Matters More Than Apparatus

For many APIs, the choice of dissolution medium (pH, buffer molarity, surfactant inclusion) drives the dissolution profile shape more than the apparatus selection does. A QC manager debating apparatus 1 versus apparatus 2 is sometimes solving the wrong problem — particularly for poorly-soluble BCS Class II or Class IV APIs where the discriminating variable is sink-condition maintenance, not stirring geometry.

Medium selection priorities, in the order a method developer should investigate them:

  • pH range of physiological relevance. USP <711> pH 1.2 (simulated gastric) for IR tablets, pH 4.5 (acetate) for ER characterization, pH 6.8 (phosphate) for intestinal-window simulation. Multi-pH gradient testing is now common for ER products targeting OGD biowaiver criteria.
  • Buffer molarity and ionic strength. A 0.05 M phosphate buffer behaves differently from a 0.1 M phosphate buffer for ionizable APIs near their pKa. The difference is measurable on the dissolution profile.
  • Surfactant inclusion for poorly-soluble APIs. Sodium lauryl sulfate (SLS) at 0.1% to 1.0% is a common addition for BCS Class II/IV APIs. The surfactant concentration must be documented as a method parameter, not a "developer's choice."
  • Degassing. USP <711> requires medium to be degassed before use — dissolved oxygen and carbon dioxide both affect dissolution profile shape, and CO2 changes the apparent pH of bicarbonate buffers. Vacuum degassing or helium sparging are standard; the method must specify which and to what residual gas level.
  • Volume. 500 mL, 900 mL, and 1000 mL are the standard volumes; small-cup configurations (250 mL or smaller) are available as accessory kits for low-dose APIs that would be below quantitation in 900 mL.

The point: when a dissolution method behaves erratically, run the medium-variable troubleshooting sequence before switching apparatus. The apparatus decision is the architectural choice; the medium decision is where most of the day-to-day method-development work actually lives.

Throughput Considerations: Sizing the Hardware to the Lab's Schedule

A common procurement mistake is buying a dissolution platform sized for current throughput rather than the throughput the lab will produce two years from now. A well-run QC operation typically grows in a stair-step pattern: a new product line, a new dosage strength, a regulatory inspection finding requiring expanded release testing. Sizing the apparatus is a 7–10 year decision.

The Huanghai dissolution range is structured to map to four distinct throughput envelopes:

  • RCZ-1B Basic Dissolution Tester — single-vessel research and method-development unit. Suitable for very-low-volume R&D, contract development organizations doing screening work, and university labs. It is a teaching and method-screening platform — it is not a release-testing solution for routine QC.
  • RCZ-6N Intelligent Dissolution Tester — 6-vessel entry-level QC platform with built-in 150 mL replenishment, suitable for small-to-medium QC operations running standard release testing on a moderate product portfolio. The 6-vessel envelope handles the USP <711> six-unit replicate requirement with no spare vessels.
  • RCZ-8N / RCZ-8A Intelligent Dissolution Tester — 8-vessel platforms (USP six-unit replicate plus two spare vessels for retesting, calibration verification, or parallel validation runs). The 8A includes an auto tablet dropper and separate stirring control suited to multi-API release testing and method development. The 8N runs simultaneous dosing for synchronized sampling.
  • RCZ-12A Intelligent Dissolution Tester — 12-vessel high-volume QC platform. The 12-vessel configuration absorbs a full dosage-strength sweep in a single run. Recommended for QC labs running 5,000+ release tests per year, contract research organizations executing dissolution profile work for ANDA submissions, and regulated facilities with a multi-product release calendar.
  • RCZ-QY12 Automatic Sampling System — 12-vessel dissolution tester paired with an automated syringe-based sampling module. The auto-sampling envelope is the right answer when the sampling-point variability becomes the dominant source of uncertainty in the dissolution profile — typically above 5,000 dissolution tests per year, or for any submission where the method demands tight control of the t = 5, 10, 15, 30, 45, 60-minute pull points without operator intervention. The high-precision imported sampling pumps are specified for repeatable volume and timing.

The throughput question is not about the number of tablets your lab tests today. It is about whether your sampling pull points can survive a year of operator turnover, weekend shift coverage, and inspection-readiness without becoming the single largest variance source in your release data.

Cross-Method Validation: What Changes When You Transfer Apparatus

A formulation developed on Apparatus 2 cannot be release-tested on Apparatus 1 (or vice versa) without a full method amendment package. The pharmacopoeial harmonization between USP, EP, JP, and ChP keeps the apparatus definitions consistent, but it does not waive the validation work that comes with switching apparatus.

When a method is being transferred or an apparatus change is being considered, the following validation deliverables must be produced:

  • Apparatus equivalence study — typically a 12-vessel comparative run between the original apparatus and the proposed apparatus, with F2 similarity factor (ƒ2 ≥ 50) demonstrated across the dissolution profile.
  • Sinker validation if Apparatus 2 is involved — the sinker geometry, mass, and material must be locked. A sinker substitution is a method change.
  • Dissolution medium and stirring-speed re-confirmation — the medium and RPM that worked on the original apparatus may not produce equivalent kinetics on the new apparatus. Confirm both before declaring equivalence.
  • Bracketing across dosage strengths — for products with multiple dosage strengths, the apparatus equivalence must be demonstrated at the lowest strength (where partial dissolution sensitivity is highest) and the highest strength (where coning risk is highest).
  • Regulatory notification — for marketed products, an apparatus change is typically a CBE-30 or PAS submission depending on the product's regulatory classification. Confirm the filing pathway with regulatory affairs before the lab work begins.

The implication for procurement: if your QC operation supports multiple ANDA submissions referencing different RLD apparatus, your dissolution platform must be configurable for both Apparatus 1 and Apparatus 2 without a mechanical retrofit. The RCZ-8N, RCZ-8A, RCZ-12A, and RCZ-QY12 platforms support both basket and paddle configurations through interchangeable shaft-and-stirrer assemblies.

Frequently Asked Questions

Q: My paddle method is producing a coning artifact. Should I switch to Apparatus 1?
A: Not as the first response. The standard sequence is: (1) verify paddle height (25 ± 2 mm above the inner vessel bottom per USP <711>), centering, and sinker placement; (2) consider increasing RPM from 50 to 75 within validated ranges; (3) evaluate medium changes (surfactant addition, ionic strength); (4) only if these fail, consider an apparatus change with the full method-amendment package that entails. Switching to Apparatus 1 is a defensible solution for buoyant or coning-prone dosage forms, but it is a method change, not a tweak.

Q: How do I validate a new sinker configuration for a paddle method?
A: Sinker validation is part of the dissolution method itself, not a separate procedure. The sinker geometry, mass, and material must be specified in the method document, and a comparative dissolution profile must demonstrate ƒ2 ≥ 50 between the proposed sinker and the previously validated sinker. A sinker change is not a like-for-like substitution even if the new sinker is from the same vendor's catalog.

Q: What is the difference between 50, 75, and 100 RPM, and how do I choose?
A: 50 RPM is the most commonly specified paddle speed for IR tablets per FDA OGD recommendations — it produces low-shear hydrodynamics that discriminate between formulation differences without overwhelming intrinsic release kinetics. 75 RPM is used for ER products and as a coning-mitigation step for IR products. 100 RPM is the typical Apparatus 1 (basket) speed for capsules and is rarely used for paddle methods outside of specific research contexts. The RPM is not a free parameter — it must be justified against the FDA OGD database for the relevant RLD or against scientifically sound method-development principles for novel formulations.

Q: What is the relationship between dissolution and disintegration testing, and do I need both?
A: Disintegration (USP <701>, ChP 0921) measures the time for a tablet or capsule to physically break down into fragments small enough to pass through a 2.0 mm mesh in the disintegration apparatus. Dissolution (USP <711>) measures the rate at which dissolved API enters the bulk medium. They are complementary, not interchangeable. For QC release testing on a routine IR tablet, both are typically required. For novel ER products or generic biowaiver-eligible IR products, dissolution testing alone may be sufficient — confirm with the regulatory authority and the relevant pharmacopoeial monograph. Some Huanghai customers consolidate both methods on the SY-6DN Intelligent 4-in-1 Tester, which integrates hardness, friability, disintegration, and dissolution testing on a single platform — useful for development labs and small QC operations standardizing on one vendor.

Q: My ANDA submission requires multi-pH dissolution profiling (pH 1.2 / 4.5 / 6.8). Do I need three separate dissolution platforms?
A: No — you need one dissolution platform with the operational discipline to reset cleanly between media. The same RCZ-8A or RCZ-12A configuration runs all three pH conditions in sequence; what matters is the cleaning validation between runs and the rigor of the medium preparation log. For high-volume submission work, the RCZ-QY12 automated sampling platform eliminates the operator-introduced timing variance that becomes the largest variance source in multi-pH profile work — particularly for the early sampling points (5, 10, 15 minutes) where timing errors of 30 seconds are statistically meaningful.

Q: Are Huanghai dissolution testers certified by an internationally recognized notified body?
A: Yes. The full RCZ dissolution tester family — RCZ-QY12, RCZ-QY8, ZQY-12A, ZQY-8A, RCZ-12A, RCZ-8A, RCZ-8N, RCZ-6N, RCZ-1B — holds CE certification under both the Machinery Directive (2006/42/EC) and EMC Directive (2014/30/EU). The certification documents are available on request via the Huanghai certifications page. Lab instruments support basic audit trails per USP/ChP standards.

Conclusion

For QC labs evaluating the apparatus 1 versus apparatus 2 decision, the calculation is structured around three questions: what dosage form does the formulation produce at t = 0, what does the FDA OGD database recommend for the RLD, and what is the projected dissolution-test volume over the next 7 to 10 years.

Encapsulated, floating, or buoyant-fragment dosage forms steer toward Apparatus 1. Conventional IR and ER tablets steer toward Apparatus 2 with disciplined coning management. The throughput conversation steers toward 6-vessel for entry-level QC, 8-vessel where USP six-unit replicate plus spare capacity is required, and 12-vessel automated sampling where dissolution-test volume crosses the threshold at which operator-introduced sampling variance becomes the dominant uncertainty source.

Specify the apparatus once, lock the method, and treat any subsequent apparatus or sinker change as the regulatory event it actually is. For configuration discussions, qualification documentation, or method-development consulting on a specific dosage form, contact the Huanghai engineering team via the contact page.

 

Back to blog

Contact us